Collectively, these results demonstrate that losartan has a profound effect on the ECM and the tumor stroma, effects which are consistent with the inhibition of TGF-β signaling and that are likely to contribute to enhancement of tumor invasion by CD8+ Teff cells. Here, CD8A is linked to neoplasm.